UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 23, 2018
Stericycle, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 1-37556 | 36-3640402 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
28161 North Keith Drive
Lake Forest, Illinois 60045
(Address of principal executive offices including zip code)
(847) 367-5910
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CR 230.425) |
☐ | Soliciting material pursuant to Rule 425 under the Securities Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
Amendments to Debt Agreements
On March 23, 2018, Stericycle, Inc. (the Company ) entered into amendments to certain of its debt agreements as described below.
First Amendment to Credit Agreement
The Company is a party to that certain Credit Agreement dated as of November 17, 2017 by and among the Company and certain of its subsidiaries named therein, Bank of America, N.A., as administrative agent, and the other financial institutions party thereto (the Bank Credit Agreement ).
On March 23, 2018, the Company entered into a First Amendment to the Bank Credit Agreement (the Bank Credit Agreement Amendment ). The Bank Credit Agreement Amendment amends the Bank Credit Agreement to, among other things, (i) modify the definition of Consolidated EBITDA to provide certain add-backs for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 for purposes of determining compliance with the leverage ratio, and (ii) modify the definition of Applicable Rate to provide a new interest rate margin pursuant to which, if, at the end of any fiscal quarter, the Consolidated Leverage Ratio (as defined in the Bank Credit Agreement) is greater than or equal to 4.00 to 1.00, then the Applicable Margin will be increased (as compared to the Applicable Margin for Pricing Level IV, which remains unchanged from the Bank Credit Agreement) by 0.20% for revolving loan borrowings, by 0.25% for term loan borrowings and by 0.05% for the facility fee payable on the amount of the revolving credit facility commitments, in each case as more fully described in the below pricing grid and in the Bank Credit Agreement Amendment.
Revolving Credit Facility | Term Facility | |||||||||||||||||||||
Level |
Consolidated Leverage Ratio |
Facility
Fee |
Eurocurrency
Rate/Letter of Credit Fee |
Base Rate |
Eurocurrency
Rate |
Base Rate | ||||||||||||||||
I |
Less than 1.75 to 1.00 | 0.100 | % | 0.900 | % | 0.000 | % | 1.000 | % | 0.000 | % | |||||||||||
II |
Greater than or equal to 1.75 to 1.00 but less than 2.50 to 1.00 | 0.120 | % | 0.980 | % | 0.000 | % | 1.110 | % | 0.110 | % | |||||||||||
III |
Greater than or equal to 2.50 to 1.00 but less than 3.25 to 1.00 | 0.150 | % | 1.050 | % | 0.050 | % | 1.200 | % | 0.200 | % | |||||||||||
IV |
Greater than or equal to 3.25 to 1.00 but less than 4.00 to 1.00 | 0.200 | % | 1.175 | % | 0.175 | % | 1.375 | % | 0.375 | % | |||||||||||
V |
Greater than or equal to 4.00 to 1.00 | 0.250 | % | 1.375 | % | 0.375 | % | 1.625 | % | 0.625 | % |
Note Purchase Agreement Amendments
The Company is a party to that certain (1) Note Purchase Agreement dated as of August 18, 2010 among the Company and the holders of notes party thereto, pursuant to which, among other things, the Company issued $225,000,000 aggregate principal amount of its 4.47% Senior Notes, Series B, due October 15, 2020, (2) First Amendment to Note Purchase Agreement dated as of August 13, 2015 among the Company and each of the institutions which is a signatory thereto, and (3) Second Amendment to Note Purchase Agreement dated as of July 28, 2017 among the Company and each of the institutions which is a signatory thereto (such Note Purchase Agreement, as amended by the amendments described in clauses (2) and (3) of this paragraph, the 2010 Note Purchase Agreement ).
The Company is a party to that certain (1) Note Purchase Agreement dated as of October 22, 2012 among the Company and the holders of notes party thereto, pursuant to which, among other things, the Company issued (a) $125,000,000 aggregate principal amount of its 2.68% Senior Notes, Series A, due December 12, 2019 and (b) $125,000,000 aggregate principal amount of its 3.26% Senior Notes, Series B, due December 12, 2022, (2) First Amendment to Note Purchase Agreement dated as of August 13, 2015 among the Company and each of the institutions which is a signatory thereto, and (3) Second Amendment to Note Purchase Agreement dated as of July 28, 2017 among the Company and each of the institutions which is a signatory thereto (such Note Purchase Agreement, as amended by the amendments described in clauses (2) and (3) of this paragraph, the 2012 Note Purchase Agreement ).
The Company is a party to that certain (1) Note Purchase Agreement dated as of April 30, 2015 among the Company and the holders of notes party thereto, (2) First Amendment to Note Purchase Agreement dated as of June 30, 2015 among the Company and each of the institutions which is a signatory thereto, pursuant to which, among other things, the Company issued (a) $200,000,000 aggregate principal amount of its 2.72% Senior Notes, Series A, due July 1, 2022 and (b) $100,000,000 aggregate principal amount of its 2.79% Senior Notes, Series B, due July 1, 2023, (3) Second Amendment to Note Purchase Agreement dated as of August 13, 2015 among the Company and each of the institutions which is a signatory thereto, and (4) Third Amendment to Note Purchase Agreement dated as of July 28, 2017 among the Company and each of the institutions which is a signatory thereto (such Note Purchase Agreement, as amended by the amendments described in clauses (2), (3) and (4) of this paragraph, the 2015A Note Purchase Agreement ).
The Company is a party to that certain (1) Note Purchase Agreement dated as of October 1, 2015 among the Company and the holders of notes party thereto, pursuant to which, among other things, the Company issued (a) $150,000,000 aggregate principal amount of its 2.89% Senior Notes, Series A, due October 1, 2021 and (b) $150,000,000 aggregate principal amount of its 3.18% Senior Notes, Series B, due October 1, 2023, and (2) First Amendment to Note Purchase Agreement dated as of July 28, 2017 among the Company and the holders of notes party thereto (as so amended, the 2015B Note Purchase Agreement and, together with the 2010 Note Purchase Agreement, the 2012 Note Purchase Agreement and the 2015A Note Purchase Agreement, the Note Purchase Agreements ).
On March 23, 2018, the Company entered into that certain (1) Third Amendment to the 2010 Note Purchase Agreement, (2) Third Amendment to the 2012 Note Purchase Agreement, (3) Fourth Amendment to the 2015A Note Purchase Agreement, and (4) Second Amendment to the 2015B Note Purchase Agreement (collectively, the NPA Amendments and, together with the Bank Credit Agreement Amendment, the Debt Agreement Amendments ).
Each of the NPA Amendments amends its respective Note Purchase Agreement to, among other things, (i) modify the definition of Consolidated EBITDA to provide certain add-backs for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 for purposes of determining compliance with the leverage ratio, and (ii) modify the financial covenant to provide that if, at the end of any fiscal quarter ending before or on December 31, 2019, the Unadjusted Consolidated Leverage Ratio (as defined in each NPA Amendment to exclude certain add-backs to Consolidated EBITDA added in the NPA Amendments) exceeded 3.75 to 1.00, the per annum interest rate otherwise applicable to such series of the notes shall be increased, in each case from the date that the Unadjusted Consolidated Leverage Ratio was in excess of 3.75 to 1.00 to but not including the date that the Unadjusted Consolidated Leverage Ratio is less than 3.75 to 1.00 as follows and, as more fully described in the NPA Amendments:
(a) by 0.50% if the Company has a rating of BBB or better by S&P (or an equivalent rating by another rating agency),
(b) by an additional 0.25% if the Company has a rating of BBB- by S&P (or an equivalent rating by another rating agency), for a total of 0.75% above the rate otherwise applicable to such series of notes, and
(c) by an additional 0.50% if the Company has no rating or a rating of BB+ or worse by S&P (or an equivalent rating by another rating agency), for a total of 1.25% above the rate otherwise applicable to such series of notes.
Other Related Matters
The representations, warranties and covenants of each of the parties contained in the Debt Agreement Amendments have been made solely for the benefit of the parties to the applicable documents. In addition, such representations, warranties and covenants (i) have been made only for purposes of the Debt Agreement Amendments, (ii) have been qualified by confidential disclosures made by the parties in connection with the Debt Agreement Amendments, (iii) are subject to materiality qualifications contained in the Debt Agreement Amendments that may differ from what may be viewed as material by investors, (iv) were made only as of the date of the Debt Agreement Amendments or such other date as is specified in the Debt Agreement Amendments and (v) have been included in the Debt Agreement Amendments for the purpose of allocating risk between the contracting parties rather than establishing matters as facts. Accordingly, the Debt Agreement Amendments are included with this filing only to provide investors with information regarding the terms of the Debt Agreement Amendments, and not to provide investors with any other factual information regarding the parties or their respective businesses. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Debt Agreement Amendments, which subsequent information may or may not be fully reflected in the public disclosures by the parties or their subsidiaries. The Debt Agreement Amendments should not be read alone, but should instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated by reference into, the Forms 10-K, Forms 10-Q and other documents that such party files with the U.S. Securities and Exchange Commission.
The foregoing summary of the Debt Agreement Amendments does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Debt Agreement Amendments attached as Exhibits 10.1 to 10.5 and incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
The following exhibits are filed with this report:
* | The Company agrees to furnish supplementally a copy of any omitted exhibit or appendix to the Securities and Exchange Commission upon request. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STERICYCLE, INC. | ||||||
Date: March 26, 2018 | By: |
/s/ Daniel V. Ginnetti |
||||
Daniel V. Ginnetti | ||||||
Executive Vice President and Chief Financial Officer |
Exhibit 10.1
EXECUTION VERSION
STERICYCLE, INC.
FIRST AMENDMENT
This FIRST AMENDMENT , dated as of March 23, 2018 (this Amendment ), is entered into by and among STERICYCLE, INC. , a Delaware corporation (the Company ), the Subsidiaries of the Company signatory hereto (collectively, the Subsidiary Loan Parties ), the Lenders (as defined below) signatory hereto and BANK OF AMERICA, N.A. , as administrative agent (in such capacity, the Administrative Agent ) under that certain Credit Agreement, dated as of November 17, 2017 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the Credit Agreement ), among the Company, the financial institutions from time to time party thereto as lenders (the Lenders ) or as L/C Issuers, the Subsidiaries of the Company party thereto as Designated Borrowers, and the Administrative Agent. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement.
W I T N E S S E T H
WHEREAS, the Company has requested that the Lenders and the Administrative Agent amend the Credit Agreement as set forth herein; and
WHEREAS, the Administrative Agent and the Lenders have agreed, on the terms and conditions set forth below, to so amend the Credit Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the parties hereto hereby agrees as follows:
1. Amendments to Credit Agreement . Subject to the satisfaction of the conditions precedent set forth in Section 2 hereof:
(a) The definition of Applicable Rate in Section 1.01 is amended to (i) delete the first reference therein to Pricing Level IV and insert Pricing Level V in lieu thereof and (ii) delete the pricing grid therein and insert the following in lieu thereof:
Revolving Credit Facility | Term Facility | |||||||||||
Level |
Consolidated Leverage Ratio |
Facility
Fee |
Eurocurrency
Rate/Letter of Credit Fee |
Base Rate | Eurocurrency Rate | Base Rate | ||||||
I |
Less than 1.75 to 1.00 | 0.100% | 0.900% | 0.000% | 1.000% | 0.000% | ||||||
II |
Greater than or equal to 1.75 to 1.00 but less than 2.50 to 1.00 | 0.120% | 0.980% | 0.000% | 1.110% | 0.110% | ||||||
III |
Greater than or equal to 2.50 to 1.00 but less than 3.25 to 1.00 | 0.150% | 1.050% | 0.050% | 1.200% | 0.200% | ||||||
IV |
Greater than or equal to 3.25 to 1.00 but less than 4.00 to 1.00 | 0.200% | 1.175% | 0.175% | 1.375% | 0.375% | ||||||
V |
Greater than or equal to 4.00 to 1.00 | 0.250% | 1.375% | 0.375% | 1.625% | 0.625% |
(b) The definition of Consolidated EBITDA in Section 1.01 is amended to add a new clause (a)(xi) to such definition that reads as follows:
and (xi) solely for purposes of determining compliance with Section 7.11 for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes hereunder, including, without limitation, for determination of the Applicable Rate), up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges
(c) The existing Exhibit D is deleted and the Exhibit D attached hereto as Annex A is inserted in lieu thereof.
2. Conditions to Effectiveness . The provisions of Section 1 of this Amendment shall be deemed to have become effective as of the date of this Amendment, but such effectiveness shall be expressly conditioned upon the following:
(a) the Administrative Agents receipt of counterparts of this Amendment, duly executed and delivered on behalf of each of the Company, each Subsidiary Loan Party and the Required Lenders;
(b) the Company having paid the fees in the amounts and at the times specified in the letter agreement, dated as of March 1, 2018, between the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated (the Amendment Fee Letter ), which fees shall be deemed fully earned and due on the effective date and shall be non-refundable;
(c) satisfactory evidence of substantially contemporaneous amendments in form and substance satisfactory to the Administrative Agent, including amendments in substance parallel to those in Section 1 of this Amendment, with respect to (x) the 2010 Note Purchase Agreement, (y) the 2012 Note Purchase Agreement, and (z) the 2015 Note Purchase Agreement; and
(d) unless waived by the Administrative Agent, the Company having paid all fees, charges and disbursements of counsel to the Administrative Agent to the extent invoiced prior to the date hereof.
3. Representations and Warranties . Each Loan Party hereby represents and warrants that:
(a) This Amendment has been duly executed and delivered by each Loan Party that is party hereto. This Amendment constitutes a legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, examinership or similar laws affecting creditors rights generally and by principles of equity);
(b) Each Loan Party (i) is duly organized or formed, validly existing and in good standing (if applicable in such Loan Partys jurisdiction of incorporation or organization) under the Laws of the jurisdiction of its incorporation or organization and (ii) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to execute, deliver and perform its obligations under this Amendment;
2
(c) The execution, delivery and performance by each Loan Party of this Amendment have been duly authorized by all necessary corporate or other organizational action, and do not and will not (i) contravene the terms of any of such Persons Organization Documents; (ii) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (A) any Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Subsidiaries or (B) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (iii) violate any Law;
(d) No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Loan Party of this Amendment;
(e) No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Amendment; and
(f) The representations and warranties contained in Article V of the Credit Agreement and the other Loan Documents are true and correct in all material respects (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects) as of such earlier date and except that the representations and warranties contained in subsections (a) and (b) of Section 5.05 thereof shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 thereof.
4. Governing Law; Jurisdiction; Waiver of Jury Trial; Etc . THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS AND DECISIONS (AS OPPOSED TO CONFLICTS OF LAW PROVISIONS) OF THE STATE OF NEW YORK. This Amendment shall be further subject to the provisions of Sections 10.14 and 10.15 of the Credit Agreement.
5. Counterparts; Integration; Effectiveness . This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Amendment, together with the Amendment Fee Letter and the other Loan Documents, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Amendment by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Amendment.
6. Severability . If any provision of this Amendment is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Amendment shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
3
7. Effect . Upon the effectiveness of this Amendment, each reference in the Credit Agreement to this Agreement, hereunder, hereof or words of like import shall mean and be a reference to the Credit Agreement as modified hereby and each reference in the other Loan Documents to the Credit Agreement, thereunder, thereof, or words of like import shall mean and be a reference to the Credit Agreement as modified hereby. This Amendment shall constitute a Loan Document for purposes of the Credit Agreement.
8. Reaffirmation . Except as specifically modified by this Amendment, the Credit Agreement shall remain in full force and effect and is hereby ratified and confirmed.
9. Guarantors . Each Guarantor hereby consents to this Amendment and reaffirms the terms and conditions of each Guaranty and each other Loan Document executed by it and acknowledges and agrees that each and every such Guaranty and other Loan Document executed by such Guarantor in connection with the Credit Agreement remains in full force and effect and is hereby reaffirmed, ratified and confirmed.
[Remainder of this page intentionally left blank; signature pages follow]
4
IN WITNESS WHEREOF, each of the undersigned has caused this Amendment to be executed and delivered by a duly authorized officer on the date first above written.
BANK OF AMERICA, N.A. , as Administrative Agent |
||
By: |
/s/ Ronaldo Naval |
Name: | Ronaldo Naval | |
Title: | Vice President | |
BANK OF AMERICA, N.A. , as a Lender, an L/C Issuer and Swing Line Lender |
By: |
/s/ Matthew N. Walt |
Name: | Matthew N. Walt | |
Title: | Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
STERICYCLE, INC. , as the Company | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Executive Vice President and Chief Financial Officer | |
STERICYCLE INTERNATIONAL, LTD. , as a Designated Borrower and a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Director | |
SRCL LIMITED , as a Designated Borrower and a Guarantor |
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Director |
STERICYCLE EUROPE S.à.r.l. , as a Designated Borrower and a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | A manager | |
STERICYCLE, ULC , as a Designated Borrower and a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Executed Vice President and Chief Financial Officer | |
STERICYCLE INTERNATIONAL HOLDINGS LIMITED , as a Designated Borrower and a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
STERICYCLE ENVIRONMENTAL SOLUTIONS, INC. , as a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Vice President, Secretary and Treasurer | |
SHRED-IT USA LLC , as a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Vice President, Secretary and Treasurer | |
STERICYCLE COMMUNICATION SOLUTIONS, INC. , as a Guarantor | ||
By: |
/s/ Daniel Ginnetti |
|
Name: | Daniel Ginnetti | |
Title: | Vice President, Secretary and Treasurer |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
STERICYCLE ESPAÑA, S.L. (Sociedad Unipersonal) ,
as a Guarantor
By: |
/s/ Franciscus J.M. Ten Brink |
|
Name: | Franciscus J.M. Ten Brink | |
Title: | Administrador Único |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
HSBC BANK USA, NATIONAL ASSOCIATION , as a Lender | ||
By: |
/s/ Matthew Brannon |
|
Name: | Matthew Brannon | |
Title: | Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
HSBC BANK PLC , as a Lender | ||
By: |
/s/ Giovanna Padua |
|
Name: | Giovanna Padua | |
Title: | Relationship Banker |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
JPMORGAN CHASE BANK, N.A. , as a Lender | ||
By: |
/s/ Krys Szrenski |
|
Name: | Krys Szrenski | |
Title: | Executive Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. , as a Lender | ||
By: |
/s/ Maria F. Maia |
|
Name: | Maria Maia | |
Title: | Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
SUMITOMO MITSUI BANKING CORPORATION , as a Lender | ||
By: |
/s/ James D. Weinstein |
|
Name: | James D. Weinstein | |
Title: | Managing Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
WELLS FARGO BANK, NATIONAL ASSOCIATION , as a Lender | ||
By: |
/s/ Sara Barton |
|
Name: | Sara Barton | |
Title: | Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
U.S. BANK NATIONAL ASSOCIATION , as a Lender | ||
By: |
/s/ James DeVries |
|
Name: | James DeVries | |
Title: | Senior Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
BMO HARRIS FINANCING INC. , as a Lender | ||
By: |
/s/ Isabella Battista |
|
Name: | Isabella Battista | |
Title: | Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
BMO HARRIS BANK N.A. , as a Lender | ||
By: |
/s/ Isabella Battista |
|
Name: | Isabella Battista | |
Title: | Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
COMPASS BANK , as a Lender | ||
By: |
/s/ April Chan |
|
Name: | ||
Title: |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
UNICREDIT BANK AG, NEW YORK BRANCH , as a Lender | ||
By: |
/s/ Ken Hamilton |
|
Name: | Ken Hamilton | |
Title: | Managing Director | |
By: |
/s/ Mathias Eichwald |
|
Name: | Mathias Eichwald | |
Title: |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
GOLDMAN SACHS BANK USA , as a Lender | ||
By: |
/s/ Chris Lam |
|
Name: | Chris Lam | |
Title: |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
CITIBANK, N.A. , as a Lender | ||
By: |
/s/ Michael Schadt |
|
Name: | Michael Schadt | |
Title: | Authorized Signatory |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
CITIZENS BANK, N.A. , as a Lender | ||
By: |
/s/ Caroline Conole |
|
Name: | Caroline Conole | |
Title: | Assistant Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
PNC BANK, NATIONAL ASSOCIATION , as a Lender |
By: |
/s/ Bridget Anderson |
|
Name: | Bridget Anderson | |
Title: | Assistant Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
SANTANDER BANK, N.A. , as a Lender | ||
By: |
/s/ Andres Barbosa |
|
Name: | Andres Barbosa | |
Title: | Executive Director | |
By: |
/s/ Daniel Kostman |
|
Name: | Daniel Kostman | |
Title: | Executive Director |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
THE NORTHERN TRUST COMPANY , as a Lender |
By: |
/s/ Brittany Mondanc |
|
Name: | Brittany Mondanc | |
Title: | Vice President |
Stericycle, Inc.
First Amendment to Credit Agreement
Signature Page
ANNEX A
EXHIBIT D
FORM OF COMPLIANCE CERTIFICATE
Financial Statement Date: ,
To: Bank of America, N.A., as Administrative Agent
Ladies and Gentlemen:
Reference is made to that certain Credit Agreement, dated as of November 17, 2017 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the Agreement ; the terms defined therein being used herein as therein defined), among Stericycle, Inc., a Delaware corporation (the Company ), the Designated Borrowers from time to time party thereto, the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer.
The undersigned Responsible Officer hereby certifies as of the date hereof that he/she is the of the Company, and that, as such, he/she is authorized to execute and deliver this Certificate to the Administrative Agent on the behalf of the Company, and that:
[Use following paragraph 1 for fiscal year-end financial statements]
1. Attached hereto as Schedule 1 are the year-end audited financial statements required by Section 6.01(a) of the Agreement for the fiscal year of the Company ended as of the above date, together with the report and opinion of an independent certified public accountant required by such section.
[Use following paragraph 1 for fiscal quarter-end financial statements]
1. Attached hereto as Schedule 1 are the unaudited financial statements required by Section 6.01(b) of the Agreement for the fiscal quarter of the Company ended as of the above date. Such financial statements fairly present the financial condition, results of operations and cash flows of the Company and its Consolidated Subsidiaries in accordance with GAAP as at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes.
2. The undersigned has reviewed and is familiar with the terms of the Agreement and has made, or has caused to be made under his/her supervision, a detailed review of the transactions and condition (financial or otherwise) of the Company during the accounting period covered by the attached financial statements.
3. A review of the activities of the Company during such fiscal period has been made under the supervision of the undersigned with a view to determining whether during such fiscal period the Company performed and observed all its Obligations under the Loan Documents, and
[select one:]
[to the best knowledge of the undersigned during such fiscal period, the Company performed and observed each covenant and condition of the Loan Documents applicable to it, and no Default has occurred and is continuing.]
or
[the following covenants or conditions have not been performed or observed and the following is a list of each such Default and its nature and status:]
4. The representations and warranties of (i) the Borrowers contained in Article V of the Agreement and (ii) each Loan Party contained in each other Loan Document or in any document furnished at any time under or in connection with the Loan Documents, are true and correct in all material respects (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects) as of such earlier date, and except that for purposes of this Compliance Certificate, the representations and warranties contained in subsections (a) and (b) of Section 5.05 of the Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Agreement, including the statements in connection with which this Compliance Certificate is delivered.
5. The financial covenant analyses and information set forth on Schedule 2 attached hereto are true and accurate on and as of the date of this Certificate.
6. Since the date of delivery of the most recent Compliance Certificate, no Persons have become Material Subsidiaries [other than ].
[signature page follows]
IN WITNESS WHEREOF , the undersigned has executed this Certificate as of , .
STERICYCLE, INC. |
By: |
Name: |
Title: |
For the Quarter/Year ended ( Statement Date )
SCHEDULE 2
to the Compliance Certificate
($ in 000s)
I. | Section 7.11 (a) Consolidated Interest Coverage Ratio. |
A. | Consolidated EBITDA for four consecutive fiscal quarters ending on above date ( Subject Period ): |
1. | Consolidated Net Income for Subject Period: | $ | ||
2. | Consolidated Interest Charges for Subject Period: | $ | ||
3. | Provision for income taxes for Subject Period: | $ | ||
4. | Depreciation expenses for Subject Period: | $ | ||
5. | Amortization expenses for Subject Period: | $ | ||
6. | Non-recurring non-cash reductions of Consolidated Net Income for Subject Period: | $ | ||
7. | Non-cash stock compensation expenses incurred in the Subject Period: | $ | ||
8. | Cash charges associated with the settlement of the TCPA Action (subject to a $45,000,000 aggregate cap) incurred in the Subject Period: | $ | ||
9. | Cash charges associated with the settlement of the MDL Contract Action (subject to a $295,000,000 aggregate cap) incurred in the Subject Period: | $ | ||
10. | Cash charges related to legal fees and expenses associated with the MDL Contract Action and related amendments to the Existing Credit Agreements and Senior Notes (subject to a $5,000,000 aggregate cap) incurred in the Subject Period: | $ | ||
12 | Transaction Costs for Subject Period: | $ | ||
13. | Extraordinary and non-recurring cash expenses or charges (subject to a $10,000,000 aggregate cap) for Subject Period: | $ |
14. | Up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges: 1 | $ | ||
15. | Income tax credits for Subject Period: | $ | ||
16. | Non-cash additions to Consolidated Net Income for Subject Period: | $ | ||
17. | Consolidated EBITDA (Lines I.A.1 + 2 + 3 + 4 + 5 + 6 +7 + 8 + 9 + 10 + 11 + 12 + 13 + 14 15 - 16): | $ |
B. | Consolidated Interest Charges for Subject Period: | $ | ||
C. | Consolidated Interest Coverage Ratio (Line I.A.17 ÷Line I.B): | to 1.00 | ||
D. | Minimum Permitted: | 3.00 to 1.00 |
II. | Section 7.11 (b) Consolidated Leverage Ratio. 2 |
A. | Consolidated Funded Indebtedness at Statement Date | $ | ||
B. | Unrestricted Cash at Statement Date | $ | ||
C. | Consolidated EBITDA for Subject Period (Line I.A.17 above): | $ | ||
D. | Consolidated Leverage Ratio ((Line II.A Line II.B) ÷ Line II.C): | to 1.00 | ||
E. | Maximum Permitted: | 3.75 to 1.00 | ||
F. | Consolidated Leverage Ratio for Subject Period for Pricing Grid Purposes ((Line II.A Line II.B) ÷ (Line II.C Line I.A.14)): | to 1.00 |
1 | Solely for purposes of determining compliance with Section 7.11 of the Credit Agreement for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes under the Credit Agreement, including, without limitation, for determination of the Applicable Rate). |
2 | If the Consolidated Leverage Ratio, on a pro forma basis as of any such date and immediately after giving effect to the settlement payment of the MDL Contract Action is greater than 3.50 to 1.00, the Company may, in its sole discretion, elect to increase the maximum Consolidated Leverage Ratio permitted by Section 7.11(b) of the Credit Agreement to 4.00 to 1.00 as of the end of the fiscal quarter in which the settlement of the MDL Contract Action occurred and in any subsequent fiscal quarter ending on or prior to September 30, 2018; provided, further , in no event shall the elevated ratio permitted by the immediately preceding proviso extend after September 30, 2018. Such election shall be made by the delivery of a written notice by the Company to the Administrative Agent making reference to Section 7.11(b) of the Credit Agreement and notifying the Administrative Agent of the Companys election to increase the maximum Consolidated Leverage Ratio as provided above on or prior to the date of the actual or required delivery of a Compliance Certificate for the fiscal quarter in which the settlement of the MDL Contract Action occurred. |
Exhibit 10.2
Execution Version
S TERICYCLE , I NC .
T HIRD A MENDMENT
Dated as of March 23, 2018
to
N OTE P URCHASE A GREEMENT
Dated as of August 18, 2010
Re: 3.89% Senior Notes, Series A, due October 15, 2017
and
4.47% Senior Notes, Series B, due October 15, 2020
T HIRD A MENDMENT TO N OTE P URCHASE A GREEMENT
T HIS T HIRD A MENDMENT dated as of March 23, 2018 (the or this Agreement ) to the Note Purchase Agreement referred to below is between S TERICYCLE , I NC ., a Delaware corporation (the Company ), and each of the institutions which is a signatory to this Agreement (collectively, the Noteholders ).
R E C I T A L S :
W HEREAS , the Company and each of the Noteholders have heretofore entered into the Note Purchase Agreement dated as of August 18, 2010, as amended by that certain First Amendment thereto dated as of August 13, 2015 and that Second Amendment dated as of July 28, 2017 (as so amended, the Note Purchase Agreement ), pursuant to which the Company issued on or about August 18, 2010 (a) $175,000,000 aggregate principal amount of its 3.89% Senior Notes, Series A, due October 15, 2017 (as amended, the Series A Notes ) and (b) $225,000,000 aggregate principal amount of its 4.47% Senior Notes, Series B, due October 15, 2020 (as amended, the Series B Notes and together with the Series A Notes, collectively, the Notes );
W HEREAS , the Company and the Noteholders now desire to amend the Note Purchase Agreement and the Notes in the respects, but only in the respects, hereinafter set forth;
W HEREAS , all capitalized terms used herein and not defined herein shall have the meaning specified in the Note Purchase Agreement;
W HEREAS , all requirements of law have been fully complied with and all other acts and things necessary to make this Agreement a valid, legal and binding instrument according to its terms for the purposes herein expressed have been done or performed.
N OW , THEREFORE , upon the full and complete satisfaction of the conditions precedent to effectiveness set forth in Section 3.1 hereof, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and each of the Noteholders do hereby agree as follows:
S ECTION 1. A MENDMENTS .
Section 1.1. Section 9.9 of the Note Purchase Agreement shall be deleted in its entirety and replaced with the words Reserved..
Section 1.2. Section 9.10 of the Note Purchase Agreement shall be and is hereby amended in its entirety as follows:
Stericycle, Inc. | Third Amendment |
Section 9.10. Note Rating. The Company will, at any time during which (a) (i) the Companys rating is A- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 1 or (b) (i) the Companys rating is BBB- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 2 or 1, at the request of the Required Holders, obtain a Private Letter Rating with respect to the Notes from one Rating Agency requested by the Required Holders.
Section 1.3. The following shall be added as new Sections 10.1(a)(iii) to the Note Purchase Agreement as follows:
(iii) If at the end of any fiscal quarter of the Company ending before or on December 31, 2019, the Unadjusted Consolidated Leverage Ratio exceeded 3.75 to 1.00, the per annum interest rate (including any Default Rate, if applicable) otherwise applicable to each series of the Notes as specified in the first paragraph thereof shall be increased as set forth below (the Primary Elevated Interest Rate ) from the date that such Unadjusted Consolidated Leverage Ratio was in excess of 3.75 to 1.00 to but not including the date that the Unadjusted Consolidated Leverage Ratio is 3.75 to 1.00 or less. The Company shall promptly, and in any event within 10 Business Days after such increase, notify the holders of the Notes in writing and specify the date of such commencement. Payment of the Primary Elevated Interest Rate shall not constitute a waiver of any Default or Event of Default hereunder. The Primary Elevated Interest Rate is determined as follows:
(A) if the Company has rating of BBB or better by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 50 basis points (0.50%);
(B) if the Company has rating of BBB- by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 75 basis points (0.75%);
(C) if the Company has no rating or a rating of BB+ or worse by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be 125 basis points (1.25%); and
(D) in the case where the Company has two ratings from two different Rating Agencies, the lowest such rating shall control and in the case where the Company has three ratings from three different Rating Agencies, then the second lowest rating shall control (even if that rating is equal to that of the first lowest).
- 2 -
Stericycle, Inc. | Third Amendment |
provided that, for the avoidance of doubt, the MDL Leverage Increased Interest Rate and the Primary Elevated Interest Rate are not cumulative with each other and only the greater of such increase under Section 10.1(a)(ii) and (iii) shall apply at any given time; and further provided that that no such Increased Interest Rate will be used in calculating the Make-Whole Amount;
Section 1.4. Additional Definitions . Schedule B to the Note Purchase Agreement is hereby amended to insert the following definitions, each in its respective alphabetical order:
Primary Elevated Interest Rate has the meaning set forth in Section 10.1(a)(iii).
Private Letter Rating means a private letter rating from a Rating Agency which (a) is in the form and include descriptive elements required by the SVO from time to time (including (i) identifying the Notes by their Private Placement Number issued by Standard & Poors CUSIP Bureau Service and (ii) addressing the likelihood of payment of both principal and interest; provided that such requirement may be deemed satisfied if the rating is silent as to such likelihood and does not otherwise include an indication to the contrary), (b) does not include any prohibition on sharing such evidence with the SVO or any other regulatory authority having jurisdiction over the holders of Notes and (c) is delivered by the Company to the holders of Notes at least annually and promptly upon any change in such rating.
Third Amendment means the Third Amendment dated as of March 23, 2018 to this Agreement between the Company and the holders party thereto.
Unadjusted Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii)
- 3 -
Stericycle, Inc. | Third Amendment |
up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements and (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Unadjusted Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Unadjusted Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Unadjusted Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Unadjusted Consolidated Leverage Ratio means, as of any date of determination, the ratio of (a)(i) Consolidated Debt as of such date minus (ii) Unrestricted Cash as of such date to (b) Unadjusted Consolidated EBITDA for the period of the four consecutive fiscal quarters most recently ended on or prior to such date.
Section 1.5. Amended Definitions. Schedule B to the Note Purchase Agreement is hereby amended by amending and restating each of the following definitions in its entirety to read as follows:
Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such
- 4 -
Stericycle, Inc. | Third Amendment |
period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements, (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and (x) solely for purposes of determining compliance with Section 10.1 and Section 10.2 for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes hereunder) up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Increased Interest Rate means the occurrence of a MDL Leverage Increased Interest Rate or a Primary Elevated Interest Rate, as applicable.
- 5 -
Stericycle, Inc. | Third Amendment |
S ECTION 2. R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY .
Section 2.1. To induce the Noteholders to execute and deliver this Agreement, the Company represents and warrants (which representations shall survive the execution and delivery of this Agreement) to the Noteholders that:
(a) this Agreement has been duly authorized, executed and delivered by the Company and, upon execution and delivery thereof by the parties hereto, this Agreement constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(b) the Note Purchase Agreement, as amended by this Agreement, constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(c) the execution, delivery and performance by the Company of this Agreement (i) has been duly authorized by all requisite corporate actions on the part of the Company, (ii) does not require the consent or approval of any governmental or regulatory body or agency, and (iii) will not (A) violate (1) any provision of law, statute, rule or regulation applicable to the Company or its certificate of incorporation or bylaws, (2) any order of any court or any rule, regulation or order of any other agency or government binding upon it, or (3) any provision of any material indenture, agreement or other instrument to which it is a party or by which its properties or assets are or may be bound, or (B) result in a breach or constitute (alone or with due notice or lapse of time or both) a default under any indenture, agreement or other instrument referred to in clause (iii)(A)(3) of this Section 2.1(c) ;
(d) as of the date hereof and after giving effect to this Agreement, no Default or Event of Default has occurred which is continuing; and
(e) the representations and warranties contained in Section 5 of the Note Purchase Agreement are true and correct in all material respects with the same force and effect as if made by the Company on and as of the date hereof, except to the extent that any such representation or warranty expressly relates to an earlier date.
- 6 -
Stericycle, Inc. | Third Amendment |
S ECTION 3. C ONDITIONS TO E FFECTIVENESS OF A MENDMENTS AND W AIVERS .
Section 3.1. The amendments to the Note Purchase Agreement set forth herein shall not become effective until, and shall become effective when (the Effective Date ), each of the following conditions shall have been satisfied:
(a) executed counterparts of this Agreement, duly executed by the Company and the holders of 51% in principal amount of the outstanding Notes, shall have been delivered to the Noteholders;
(b) the representations and warranties of the Company set forth in Section 2 hereof shall be true and correct on and with respect to the date hereof, and the execution and delivery by the Company of this Agreement shall constitute certification by the Company of the same;
(c) the Company shall have paid a fee to each holder of Notes equal to five basis points (.05%) on the outstanding principal amount of Notes held by each such holder of a Note as of the Effective Date;
(d) the Company shall have paid the fees and expenses of Chapman and Cutler LLP, special counsel to the Noteholders, incurred in connection with the negotiation, preparation, approval, execution and delivery of this Agreement for which an invoice has been provided;
(e) the Company shall have delivered copies of an amendment to each of the Bank Credit Agreement amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement; and
(f) the Company shall have delivered copies of an amendment to each of the Other Note Agreements (as defined in the Note Purchase Agreement after giving effect to this Agreement) between the Company and the purchasers named therein, each amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement.
Upon receipt and satisfaction of all of the foregoing, such amendments shall become effective.
S ECTION 4. M ISCELLANEOUS .
Section 4.1. This Agreement shall be construed in connection with and as part of the Note Purchase Agreement, and except as modified and expressly amended by this Agreement, all terms, conditions and covenants contained in the Note Purchase Agreement are hereby ratified and confirmed and shall be and remain in full force and effect.
Section 4.2 . Any and all notices, requests, certificates and other instruments, including the Notes, may refer to the Note Purchase Agreement or the Note Purchase Agreement dated as of August 18, 2010 without making specific reference to this Agreement, but nevertheless all such references shall be deemed to include this Agreement unless the context shall otherwise require.
- 7 -
Stericycle, Inc. | Third Amendment |
Section 4.3. The descriptive headings of the various Sections or parts of this Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions hereof.
Section 4.4. This Agreement shall be governed by and construed in accordance with New York law excluding choice-of-law principles of the law of New York that would require the application of the laws of jurisdiction other than New York.
Section 4.5. This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original, but all together only one agreement. This Agreement, together with the Note Purchase Agreement (as amended hereby) and the Notes, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.
- 8 -
I N W ITNESS W HEREOF , the parties hereto have executed this Agreement as of the Effective Date.
S TERICYCLE , I NC . | ||
By |
/s/ Daniel Ginnetti |
|
Name: Daniel Ginnetti | ||
Title: Executive Vice President and Chief | ||
Financial Officer |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
M ETROPOLITAN L IFE I NSURANCE C OMPANY | ||
By |
/s/ John A. Wills |
|
Name: John A. Wills | ||
Title: Senior Vice President and Managing Director | ||
U NION F IDELITY L IFE I NSURANCE C OMPANY by MetLife Investment Advisors, LLC, Its Investment Manager |
||
By |
/s/ Frank O. Monfalcone |
|
Name: Frank O. Monfalcone | ||
Title: Managing Director | ||
L INCOLN B ENEFIT L IFE C OMPANY by MetLife Investment Advisors, LLC, Its Investment Manager |
||
By |
/s/ Frank O. Monfalcone |
|
Name: Frank O. Monfalcone | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
A LLSTATE L IFE I NSURANCE C OMPANY OF | ||
N EW Y ORK | ||
By |
/s/ Ryan Anderson |
|
Name: Ryan Anderson | ||
By |
/s/ Jerry D. Zinkula |
|
Name: Jerry D. Zinkula | ||
Authorized Signatories: | ||
A MERICAN H ERITAGE L IFE I NSURANCE C OMPANY | ||
By |
/s/ Ryan Anderson |
|
Name: Ryan Anderson | ||
By |
/s/ Jerry D. Zinkula |
|
Name: Jerry D. Zinkula | ||
Authorized Signatories: |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
N EW Y ORK L IFE I NSURANCE C OMPANY | ||
By |
/s/ Clara Fagan |
|
Name: Clara Fagan | ||
Title: Corporate Vice President | ||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION |
||
By | NYL Investors LLC, its Investment Manager | |
By |
/s/ Clara Fagan |
|
Name: Clara Fagan | ||
Title: Director | ||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION I NSTITUTIONALLY O WNED L IFE I NSURANCE S EPARATE A CCOUNT (BOLI 30C) |
||
By | NYL Investors LLC, its Investment Manager | |
By |
/s/ Clara Fagan |
|
Name: Clara Fagan | ||
Title: Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
H ARTFORD L IFE I NSURANCE C OMPANY | ||
H ARTFORD L IFE AND A CCIDENT I NSURANCE C OMPANY | ||
H ARTFORD F IRE I NSURANCE C OMPANY | ||
By: | Hartford Investment Management Company | |
Their Agent and Attorney-in-Fact | ||
By |
/s/ Dawn Crunden |
|
Name: Dawn Crunden | ||
Title: Senior Vice President |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
N ATIONWIDE L IFE I NSURANCE C OMPANY | ||
N ATIONWIDE L IFE AND A NNUITY I NSURANCE C OMPANY | ||
By |
/s/ Cristian I. Donoso |
|
Name: Cristian I. Donoso | ||
Title: Authorized Signatory |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
R IVER S OURCE L IFE I NSURANCE C OMPANY | ||
By |
/s/ Thomas W. Murphy |
|
Name: Thomas W. Murphy | ||
Title: Vice PresidentInvestments |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
T HRIVENT F INANCIAL FOR L UTHERANS | ||
By |
/s/ Christopher Patton |
|
Name: Christopher Patton | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
T HE L INCOLN N ATIONAL L IFE I NSURANCE C OMPANY |
||
By: | Macquarie Investment Management Advisers, a series of Macquarie Investment Management Business Trust, Attorney-In-Fact | |
By |
/s/ Philip Lee |
|
Name: Philip Lee | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY |
||
By: | Northwestern Mutual Investment Management Company, LLC, its investment adviser | |
By |
/s/ Michael H. Leske |
|
Name: Michael H. Leske | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
J ACKSON N ATIONAL L IFE I NSURANCE C OMPANY | ||
By: | PPM America, Inc., as attorney in fact, | |
on behalf of Jackson National Life Insurance Company | ||
By |
/s/ Luke S. Stifflear |
|
Name: Luke S. Stifflear | ||
Title: Sr. Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
A LLIANZ L IFE I NSURANCE C OMPANY OF N ORTH A MERICA |
||
By: | Allianz Global Investors U.S. LLC As the authorized signatory and investment manager |
By |
/s/ Lawrence Halliday |
|
Name: Lawrence Halliday | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
S OUTHERN F ARM B UREAU L IFE I NSURANCE C OMPANY |
||
By |
/s/ David Divine |
|
Name: David Divine | ||
Title: Senior Portfolio Manager |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
M ODERN W OODMEN OF A MERICA | ||
By |
/s/ Aaron R. Birkland |
|
Name: Aaron R. Birkland | ||
Title: Portfolio Manager, Private Placements | ||
By |
/s/ Christopher M. Cramer |
|
Name: Christopher M. Cramer | ||
Title: Manager, Fixed Income |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
U NITED OF O MAHA L IFE I NSURANCE C OMPANY |
||
By |
/s/ Justin P. Kavan |
|
Name: Justin P. Kavan |
||
Title: Senior Vice President |
||
C OMPANION L IFE I NSURANCE C OMPANY |
||
By |
/s/ Justin P. Kavan |
|
Name: Justin P. Kavan |
||
Title: An Authorized Signer |
||
M UTUAL OF O MAHA I NSURANCE C OMPANY |
||
By |
/s/ Justin P. Kavan |
|
Name: Justin P. Kavan |
||
Title: Senior Vice President |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
W OODMEN OF THE W ORLD L IFE I NSURANCE S OCIETY |
||
By |
/s/ Shawn Bengtson |
|
Name: Shawn Bengtson | ||
Title: Vice President, Investment |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
K NIGHTS OF C OLUMBUS |
||
By |
/s/ Gilles Marchand |
|
Name: Gilles Marchand |
||
Title: VP, Credit Portfolio Manager |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
C OUNTRY L IFE I NSURANCE C OMPANY |
||
By |
/s/ John A. Jacobs |
|
Name: John A. Jacobs |
||
Title: Director Fixed Income |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Accepted and Agreed to:
P HYSICIANS M UTUAL I NSURANCE C OMPANY | ||
By: | Prudential Private Placement Investors, L.P. (as Investment Advisor) | |
By: | Prudential Private Placement Investors, Inc. (as its General Partner) | |
By |
/s/ Dianna Carr |
|
Name: Dianna Carr | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2010 Note Purchase Agreement |
Exhibit 10.3
Execution Version
S TERICYCLE , I NC .
T HIRD A MENDMENT
Dated as of March 23, 2018
to
N OTE P URCHASE A GREEMENT
Dated as of October 22, 2012
Re: 2.68% Senior Notes, Series A, due December 12, 2019
and
3.26% Senior Notes, Series B, due December 12, 2022
T HIRD A MENDMENT TO N OTE P URCHASE A GREEMENT
T HIS T HIRD A MENDMENT dated as of March 23, 2018 (the or this Agreement ) to the Note Purchase Agreement referred to below is between S TERICYCLE , I NC ., a Delaware corporation (the Company ), and each of the institutions which is a signatory to this Agreement (collectively, the Noteholders ).
R E C I T A L S :
W HEREAS , the Company and each of the Noteholders have heretofore entered into the Note Purchase Agreement dated as of October 22, 2012, as amended by that certain First Amendment thereto dated as of August 13, 2015 and that Second Amendment dated as of July 28, 2017 (as so amended, the Note Purchase Agreement ), pursuant to which the Company issued on or about October 22, 2012 (a) $125,000,000 aggregate principal amount of its 2.68% Senior Notes, Series A, due December 12, 2019 (as amended, the Series A Notes ) and (b) $125,000,000 aggregate principal amount of its 3.26% Senior Notes, Series B, due December 12, 2022 (as amended, the Series B Notes and together with the Series A Notes, collectively, the Notes );
W HEREAS , the Company and the Noteholders now desire to amend the Note Purchase Agreement and the Notes in the respects, but only in the respects, hereinafter set forth;
W HEREAS , all capitalized terms used herein and not defined herein shall have the meaning specified in the Note Purchase Agreement;
W HEREAS , all requirements of law have been fully complied with and all other acts and things necessary to make this Agreement a valid, legal and binding instrument according to its terms for the purposes herein expressed have been done or performed.
N OW , THEREFORE , upon the full and complete satisfaction of the conditions precedent to effectiveness set forth in Section 3.1 hereof, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and each of the Noteholders do hereby agree as follows:
S ECTION 1. A MENDMENTS .
Section 1.1. Section 9.9 of the Note Purchase Agreement shall be deleted in its entirety and replaced with the words Reserved..
Section 1.2. Section 9.10 of the Note Purchase Agreement shall be and is hereby amended in its entirety as follows:
Stericycle, Inc. | Third Amendment |
Section 9.10. Note Rating. The Company will, at any time during which (a) (i) the Companys rating is A- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 1 or (b) (i) the Companys rating is BBB- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 2 or 1, at the request of the Required Holders, obtain a Private Letter Rating with respect to the Notes from one Rating Agency requested by the Required Holders.
Section 1.3. The following shall be added as new Sections 10.1(a)(iii) to the Note Purchase Agreement as follows:
(iii) If at the end of any fiscal quarter of the Company ending before or on December 31, 2019, the Unadjusted Consolidated Leverage Ratio exceeded 3.75 to 1.00, the per annum interest rate (including any Default Rate, if applicable) otherwise applicable to each series of the Notes as specified in the first paragraph thereof shall be increased as set forth below (the Primary Elevated Interest Rate ) from the date that such Unadjusted Consolidated Leverage Ratio was in excess of 3.75 to 1.00 to but not including the date that the Unadjusted Consolidated Leverage Ratio is 3.75 to 1.00 or less. The Company shall promptly, and in any event within 10 Business Days after such increase, notify the holders of the Notes in writing and specify the date of such commencement. Payment of the Primary Elevated Interest Rate shall not constitute a waiver of any Default or Event of Default hereunder. The Primary Elevated Interest Rate is determined as follows:
(A) if the Company has rating of BBB or better by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 50 basis points (0.50%);
(B) if the Company has rating of BBB- by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 75 basis points (0.75%);
(C) if the Company has no rating or a rating of BB+ or worse by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be 125 basis points (1.25%); and
(D) in the case where the Company has two ratings from two different Rating Agencies, the lowest such rating shall control and in the case where the Company has three ratings from three different Rating Agencies, then the second lowest rating shall control (even if that rating is equal to that of the first lowest).
- 2 -
Stericycle, Inc. | Third Amendment |
provided that, for the avoidance of doubt, the MDL Leverage Increased Interest Rate and the Primary Elevated Interest Rate are not cumulative with each other and only the greater of such increase under Section 10.1(a)(ii) and (iii) shall apply at any given time; and further provided that that no such Increased Interest Rate will be used in calculating the Make-Whole Amount;
Section 1.4. Additional Definitions . Schedule B to the Note Purchase Agreement is hereby amended to insert the following definitions, each in its respective alphabetical order:
Primary Elevated Interest Rate has the meaning set forth in Section 10.1(a)(iii).
Private Letter Rating means a private letter rating from a Rating Agency which (a) is in the form and include descriptive elements required by the SVO from time to time (including (i) identifying the Notes by their Private Placement Number issued by Standard & Poors CUSIP Bureau Service and (ii) addressing the likelihood of payment of both principal and interest; provided that such requirement may be deemed satisfied if the rating is silent as to such likelihood and does not otherwise include an indication to the contrary), (b) does not include any prohibition on sharing such evidence with the SVO or any other regulatory authority having jurisdiction over the holders of Notes and (c) is delivered by the Company to the holders of Notes at least annually and promptly upon any change in such rating.
Third Amendment means the Third Amendment dated as of March 23, 2018 to this Agreement between the Company and the holders party thereto.
Unadjusted Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of
- 3 -
Stericycle, Inc. | Third Amendment |
cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements and (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Unadjusted Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Unadjusted Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Unadjusted Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Unadjusted Consolidated Leverage Ratio means, as of any date of determination, the ratio of (a)(i) Consolidated Debt as of such date minus (ii) Unrestricted Cash as of such date to (b) Unadjusted Consolidated EBITDA for the period of the four consecutive fiscal quarters most recently ended on or prior to such date.
Section 1.5. Amended Definitions. Schedule B to the Note Purchase Agreement is hereby amended by amending and restating each of the following definitions in its entirety to read as follows:
Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such
- 4 -
Stericycle, Inc. | Third Amendment |
Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements, (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and (x) solely for purposes of determining compliance with Section 10.1 and Section 10.2 for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes hereunder) up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Increased Interest Rate means the occurrence of a MDL Leverage Increased Interest Rate or a Primary Elevated Interest Rate, as applicable.
- 5 -
Stericycle, Inc. | Third Amendment |
S ECTION 2. R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY .
Section 2.1. To induce the Noteholders to execute and deliver this Agreement, the Company represents and warrants (which representations shall survive the execution and delivery of this Agreement) to the Noteholders that:
(a) this Agreement has been duly authorized, executed and delivered by the Company and, upon execution and delivery thereof by the parties hereto, this Agreement constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(b) the Note Purchase Agreement, as amended by this Agreement, constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(c) the execution, delivery and performance by the Company of this Agreement (i) has been duly authorized by all requisite corporate actions on the part of the Company, (ii) does not require the consent or approval of any governmental or regulatory body or agency, and (iii) will not (A) violate (1) any provision of law, statute, rule or regulation applicable to the Company or its certificate of incorporation or bylaws, (2) any order of any court or any rule, regulation or order of any other agency or government binding upon it, or (3) any provision of any material indenture, agreement or other instrument to which it is a party or by which its properties or assets are or may be bound, or (B) result in a breach or constitute (alone or with due notice or lapse of time or both) a default under any indenture, agreement or other instrument referred to in clause (iii)(A)(3) of this Section 2.1(c) ;
(d) as of the date hereof and after giving effect to this Agreement, no Default or Event of Default has occurred which is continuing; and
(e) the representations and warranties contained in Section 5 of the Note Purchase Agreement are true and correct in all material respects with the same force and effect as if made by the Company on and as of the date hereof, except to the extent that any such representation or warranty expressly relates to an earlier date.
S ECTION 3. C ONDITIONS TO E FFECTIVENESS OF A MENDMENTS AND W AIVERS .
Section 3.1. The amendments to the Note Purchase Agreement set forth herein shall not become effective until, and shall become effective when (the Effective Date ), each of the following conditions shall have been satisfied:
- 6 -
Stericycle, Inc. | Third Amendment |
(a) executed counterparts of this Agreement, duly executed by the Company and the holders of 51% in principal amount of the outstanding Notes, shall have been delivered to the Noteholders;
(b) the representations and warranties of the Company set forth in Section 2 hereof shall be true and correct on and with respect to the date hereof, and the execution and delivery by the Company of this Agreement shall constitute certification by the Company of the same;
(c) the Company shall have paid a fee to each holder of Notes equal to five basis points (.05%) on the outstanding principal amount of Notes held by each such holder of a Note as of the Effective Date;
(d) the Company shall have paid the fees and expenses of Chapman and Cutler LLP, special counsel to the Noteholders, incurred in connection with the negotiation, preparation, approval, execution and delivery of this Agreement for which an invoice has been provided;
(e) the Company shall have delivered copies of an amendment to each of the Bank Credit Agreement amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement; and
(f) the Company shall have delivered copies of an amendment to each of the Other Note Agreements (as defined in the Note Purchase Agreement after giving effect to this Agreement) between the Company and the purchasers named therein, each amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement.
Upon receipt and satisfaction of all of the foregoing, such amendments shall become effective.
S ECTION 4. M ISCELLANEOUS .
Section 4.1. This Agreement shall be construed in connection with and as part of the Note Purchase Agreement, and except as modified and expressly amended by this Agreement, all terms, conditions and covenants contained in the Note Purchase Agreement are hereby ratified and confirmed and shall be and remain in full force and effect.
Section 4.2 . Any and all notices, requests, certificates and other instruments, including the Notes, may refer to the Note Purchase Agreement or the Note Purchase Agreement dated as of October 22, 2012 without making specific reference to this Agreement, but nevertheless all such references shall be deemed to include this Agreement unless the context shall otherwise require.
- 7 -
Stericycle, Inc. | Third Amendment |
Section 4.3. The descriptive headings of the various Sections or parts of this Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions hereof.
Section 4.4. This Agreement shall be governed by and construed in accordance with New York law excluding choice-of-law principles of the law of New York that would require the application of the laws of jurisdiction other than New York.
Section 4.5. This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original, but all together only one agreement. This Agreement, together with the Note Purchase Agreement (as amended hereby) and the Notes, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.
- 8 -
I N W ITNESS W HEREOF , the parties hereto have executed this Agreement as of the Effective Date.
S TERICYCLE , I NC . |
||||
By |
/s/ Daniel Ginnetti |
|||
Name: | Daniel Ginnetti | |||
Title: | Executive Vice President and Chief | |||
Financial Officer |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY |
||||
By |
Northwestern Mutual Investment
Management Company, LLC, its investment adviser |
|||
By |
/s/ Michael H. Leske |
|||
Name: Michael H. Leske | ||||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
T HE L INCOLN N ATIONAL L IFE I NSURANCE C OMPANY |
||
By: | Macquarie Investment Management Advisers, a series of Macquarie Investment Management Business Trust, Attorney In Fact | |
By: |
/s/ Philip Lee |
|
Name: Philip Lee | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
V OYA R ETIREMENT I NSURANCE AND A NNUITY C OMPANY (f/k/a ING Life Insurance and Annuity Company) |
||
V
OYA
I
NSURANCE
AND
A
NNUITY
C
OMPANY
Company) |
||
R ELIASTAR L IFE I NSURANCE C OMPANY | ||
R ELIASTAR L IFE I NSURANCE C OMPANY OF N EW Y ORK |
||
By: | Voya Investment Management LLC, as Agent | |
By: |
/s/ Justin Stach |
|
Name: Justin Stach | ||
Title: Vice President | ||
NN L IFE I NSURANCE C OMPANY L TD . | ||
By: | Voya Investment Management LLC, as Attorney in fact | |
By: |
/s/ Justin Stach |
|
Name: Justin Stach | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
S YMETRA L IFE I NSURANCE C OMPANY | ||
By: |
MetLife Investment Advisors, LLC, Its
Investment Manager |
|
By: |
/s/ Judith A. Gulotta |
|
Name: Judith A. Gulotta | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
J ACKSON N ATIONAL L IFE I NSURANCE C OMPANY | ||
By: | PPM America, Inc., as attorney in fact, on behalf of Jackson National Life Insurance Company | |
By |
/s/ Luke S. Stifflear |
|
Name: Luke S. Stifflear | ||
Title: Sr. Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
T HRIVENT F INANCIAL FOR L UTHERANS | ||
By |
/s/ Christopher Patton |
|
Name: Christopher Patton | ||
Title: Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
MONY L IFE I NSURANCE C OMPANY | ||
By |
/s/ Philip E Passafiume |
|
Name: Philip E. Passafiume | ||
Title: Director, Fixed Income |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
R IVER S OURCE L IFE I NSURANCE C OMPANY | ||
By |
/s/ Thomas W. Murphy |
|
Name: Thomas W. Murphy | ||
Title: Vice President Investments | ||
R IVER S OURCE L IFE I NSURANCE C O . OF N EW Y ORK | ||
By |
/s/ Thomas W. Murphy |
|
Name: Thomas W. Murphy | ||
Title: Vice President Investments |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
W ESTERN -S OUTHERN L IFE A SSURANCE C OMPANY | ||
By |
/s/ Daniel R. Larsen |
|
Name: Daniel R. Larsen | ||
Title: Vice President | ||
By |
/s/ Jeffrey L. Stainton |
|
Name: Jeffrey L. Stainton | ||
Title: Vice President | ||
C OLUMBUS L IFE I NSURANCE C OMPANY | ||
By |
/s/ Daniel R. Larsen |
|
Name: Daniel R. Larsen | ||
Title: Vice President | ||
By |
/s/ Kevin L. Howard |
|
Name: Kevin L. Howard | ||
Title: Vice President | ||
I NTEGRITY L IFE I NSURANCE C OMPANY | ||
By |
/s/ Daniel R. Larsen |
|
Name: Daniel R. Larsen | ||
Title: Vice President | ||
By |
/s/ Kevin L. Howard |
|
Name: Kevin L. Howard | ||
Title: Senior Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
I NTEGRITY L IFE I NSURANCE C OMPANY S EPARATE A CCOUNT GPO | ||
By |
/s/ Daniel R. Larsen |
|
Name: Daniel R. Larsen | ||
Title: Vice President | ||
By |
/s/ Kevin L. Howard |
|
Name: Kevin L. Howard | ||
Title: Senior Vice President | ||
N ATIONAL I NTEGRITY L IFE I NSURANCE C OMPANY S EPARATE A CCOUNT GPO | ||
By |
/s/ Daniel R. Larsen |
|
Name: Daniel R. Larsen | ||
Title: Vice President | ||
By |
/s/ Kevin L. Howard |
|
Name: Kevin L. Howard | ||
Title: Senior Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
G REAT -W EST L IFE & A NNUITY I NSURANCE C OMPANY |
||
By |
/s/ Eve Hampton Darrow |
|
Name: Eve Hampton Darrow | ||
Title: Vice President, Investments | ||
By |
/s/ Ward Argust |
|
Name: Ward Argust | ||
Title: Assistance Vice President, Investments | ||
G REAT -W EST L IFE & A NNUITY I NSURANCE C OMPANY OF S OUTH C AROLINA |
||
By |
/s/ Eve Hampton Darrow |
|
Name: Eve Hampton Darrow | ||
Title: Authorized Signatory | ||
By |
/s/ Ward Argust |
|
Name: Ward Argust | ||
Title: Authorized Signatory |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
H ARTFORD L IFE I NSURANCE C OMPANY | ||
By: |
Hartford Investment Management Company, its Agent and Attorney and Attorney-in-Fact |
|
By |
/s/ Dawn Crunden |
|
Name: Dawn Crunden | ||
Title: Senior Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
T HE G UARDIAN L IFE I NSURANCE C OMPANY OF A MERICA |
||
By |
/s/ Amy Carroll |
|
Name: Amy Carroll | ||
Title: Senior Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
M ODERN W OODMEN OF A MERICA | ||
By |
/s/ Aaron R. Birkland |
|
Name: Aaron R. Birkland | ||
Title: Portfolio Manager, Private Placements | ||
By |
/s/ Christopher M. Cramer |
|
Name: Christopher M. Cramer | ||
Title: Manager, Fixed Income |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
T RINITY U NIVERSAL I NSURANCE C OMPANY |
C ATHOLIC U NITED F INANCIAL |
O CCIDENTAL L IFE I NSURANCE C OMPANY OF |
N ORTH C AROLINA |
W ESTERN F RATERNAL L IFE A SSOCIATION |
By: Advantus Capital Management, Inc. |
By: /s/ Thomas B. Houghton | ||
Name: Thomas B. Houghton | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
S OUTHERN F ARM L IFE I NSURANCE C OMPANY | ||
By |
/s/ David Divine |
|
Name: David Divine | ||
Title: Senior Portfolio Manager |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
W OODMEN OF THE W ORLD L IFE I NSURANCE S OCIETY |
||
By |
/s/ Shawn Bengtson |
|
Name: Shawn Bengtson | ||
Title: Vice President, Investment |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
A MERICAN U NITED L IFE I NSURANCE C OMPANY | ||
By: |
/s/ Michael I. Bullock |
|
Name: Michael I. Bullock | ||
Title: VP, Private Placements |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
A MERITAS L IFE I NSURANCE C ORP . SUCCESSOR BY MERGER TO A CACIA L IFE I NSURANCE C OMPANY |
||
A MERITAS L IFE I NSURANCE C ORP . SUCCESSOR BY MERGER TO T HE U NION C ENTRAL L IFE I NSURANCE C OMPANY |
||
A MERITAS L IFE I NSURANCE C ORP . OF N EW Y ORK | ||
By : Ameritas Investment Partners, Inc., as Agent | ||
By |
/s/ Tina Udell |
|
Name: Tina Udell | ||
Title: Vice President & Managing Director |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
USAA L IFE I NSURANCE C OMPANY | ||
By |
/s/ James F. Jackson, Jr. |
|
Name: James F. Jackson, Jr. | ||
Title: Assistant Vice President | ||
U NITED S ERVICES A UTOMOBILE A SSOCIATION | ||
By |
/s/ James F. Jackson, Jr. |
|
Name: James F. Jackson, Jr. | ||
Title: Assistant Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
C OUNTRY L IFE I NSURANCE C OMPANY | ||
By |
/s/ John A. Jacobs |
|
Name: John A. Jacobs | ||
Title: Director Fixed Income |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
P RO A SSURANCE C ASUALTY C OMPANY | ||
P RO A SSURANCE I NDEMNITY C OMPANY , I NC . | ||
By: Prime Advisors, Inc., its Attorney-in-Fact | ||
By: |
/s/ Naomi U Joy |
|
Name: Naomi U Joy | ||
Title: Vice President |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Accepted and Agreed to:
S TATE OF W ISCONSIN I NVESTMENT B OARD | ||
By |
/s/ Christopher P. Prestigiacomo |
|
Name: Christopher P. Prestigiacomo | ||
Title: Portfolio Manager |
Stericycle, Inc. | Third Amendment to | |||
2012 Note Purchase Agreement |
Exhibit 10.4
Execution Version
S TERICYCLE , I NC .
F OURTH A MENDMENT
Dated as of March 23, 2018
to
N OTE P URCHASE A GREEMENT
Dated as of April 30, 2015
Re: | 2.67% Senior Notes, Series A, due July 1, 2022 |
and
2.74% Senior Notes, Series B, due July 1, 2023
F OURTH A MENDMENT TO N OTE P URCHASE A GREEMENT
T HIS F OURTH A MENDMENT dated as of March 23, 2018 (the or this Agreement ) to the Note Purchase Agreement referred to below is between S TERICYCLE , I NC ., a Delaware corporation (the Company ), and each of the institutions which is a signatory to this Agreement (collectively, the Noteholders ).
R E C I T A L S :
W HEREAS , the Company and each of the Noteholders have heretofore entered into the Note Purchase Agreement dated as of April 30, 2015, as amended by that certain First Amendment thereto dated as of June 30, 2015, that certain Second Amendment dated as of August 30, 2015 and that Third Amendment dated as of July 28, 2017 (as so amended, the Note Purchase Agreement ), pursuant to which the Company issued on or about April 30, 2015 (a) $250,000,000 aggregate principal amount of its 2.67% Senior Notes, Series A, due July 1, 2022 (as amended, the Series A Notes ) and (b) $100,000,000 aggregate principal amount of its 2.74% Senior Notes, Series B, due July 1, 2023 (as amended, the Series B Notes and together with the Series A Notes, collectively, the Notes );
W HEREAS , the Company and the Noteholders now desire to amend the Note Purchase Agreement and the Notes in the respects, but only in the respects, hereinafter set forth;
W HEREAS , all capitalized terms used herein and not defined herein shall have the meaning specified in the Note Purchase Agreement;
W HEREAS , all requirements of law have been fully complied with and all other acts and things necessary to make this Agreement a valid, legal and binding instrument according to its terms for the purposes herein expressed have been done or performed.
N OW , THEREFORE , upon the full and complete satisfaction of the conditions precedent to effectiveness set forth in Section 3.1 hereof, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and each of the Noteholders do hereby agree as follows:
S ECTION 1. A MENDMENTS .
Section 1.1. Section 9.9 of the Note Purchase Agreement shall be deleted in its entirety and replaced with the words Reserved..
Section 1.2. Section 9.10 of the Note Purchase Agreement shall be and is hereby amended in its entirety as follows:
Stericycle, Inc. | Fourth Amendment |
Section 9.10. Note Rating. The Company will, at any time during which (a) (i) the Companys rating is A- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 1 or (b) (i) the Companys rating is BBB- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 2 or 1, at the request of the Required Holders, obtain a Private Letter Rating with respect to the Notes from one Rating Agency requested by the Required Holders.
Section 1.3. The following shall be added as new Sections 10.1(a)(iii) to the Note Purchase Agreement as follows:
(iii) If at the end of any fiscal quarter of the Company ending before or on December 31, 2019, the Unadjusted Consolidated Leverage Ratio exceeded 3.75 to 1.00, the per annum interest rate (including any Default Rate, if applicable) otherwise applicable to each series of the Notes as specified in the first paragraph thereof shall be increased as set forth below (the Primary Elevated Interest Rate ) from the date that such Unadjusted Consolidated Leverage Ratio was in excess of 3.75 to 1.00 to but not including the date that the Unadjusted Consolidated Leverage Ratio is 3.75 to 1.00 or less. The Company shall promptly, and in any event within 10 Business Days after such increase, notify the holders of the Notes in writing and specify the date of such commencement. Payment of the Primary Elevated Interest Rate shall not constitute a waiver of any Default or Event of Default hereunder. The Primary Elevated Interest Rate is determined as follows:
(A) if the Company has rating of BBB or better by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 50 basis points (0.50%);
(B) if the Company has rating of BBB- by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 75 basis points (0.75%);
(C) if the Company has no rating or a rating of BB+ or worse by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be 125 basis points (1.25%); and
(D) in the case where the Company has two ratings from two different Rating Agencies, the lowest such rating shall control and in the case where the Company has three ratings from three different Rating Agencies, then the second lowest rating shall control (even if that rating is equal to that of the first lowest).
- 2 -
Stericycle, Inc. | Fourth Amendment |
provided that, for the avoidance of doubt, the MDL Leverage Increased Interest Rate and the Primary Elevated Interest Rate are not cumulative with each other and only the greater of such increase under Section 10.1(a)(ii) and (iii) shall apply at any given time; and further provided that that no such Increased Interest Rate will be used in calculating the Make-Whole Amount;
Section 1.4. Additional Definitions . Schedule B to the Note Purchase Agreement is hereby amended to insert the following definitions, each in its respective alphabetical order:
Fourth Amendment means the Fourth Amendment dated as of March 23, 2018 to this Agreement between the Company and the holders party thereto.
Primary Elevated Interest Rate has the meaning set forth in Section 10.1(a)(iii).
Private Letter Rating means a private letter rating from a Rating Agency which (a) is in the form and include descriptive elements required by the SVO from time to time (including (i) identifying the Notes by their Private Placement Number issued by Standard & Poors CUSIP Bureau Service and (ii) addressing the likelihood of payment of both principal and interest; provided that such requirement may be deemed satisfied if the rating is silent as to such likelihood and does not otherwise include an indication to the contrary), (b) does not include any prohibition on sharing such evidence with the SVO or any other regulatory authority having jurisdiction over the holders of Notes and (c) is delivered by the Company to the holders of Notes at least annually and promptly upon any change in such rating.
Unadjusted Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii)
- 3 -
Stericycle, Inc. | Fourth Amendment |
up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements and (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Unadjusted Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Unadjusted Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Unadjusted Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Unadjusted Consolidated Leverage Ratio means, as of any date of determination, the ratio of (a)(i) Consolidated Debt as of such date minus (ii) Unrestricted Cash as of such date to (b) Unadjusted Consolidated EBITDA for the period of the four consecutive fiscal quarters most recently ended on or prior to such date.
Section 1.5. Amended Definitions. Schedule B to the Note Purchase Agreement is hereby amended by amending and restating each of the following definitions in its entirety to read as follows:
Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such
- 4 -
Stericycle, Inc. | Fourth Amendment |
period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements, (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and (x) solely for purposes of determining compliance with Section 10.1 and Section 10.2 for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes hereunder) up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Increased Interest Rate means the occurrence of a MDL Leverage Increased Interest Rate or a Primary Elevated Interest Rate, as applicable.
- 5 -
Stericycle, Inc. | Fourth Amendment |
S ECTION 2. R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY .
Section 2.1. To induce the Noteholders to execute and deliver this Agreement, the Company represents and warrants (which representations shall survive the execution and delivery of this Agreement) to the Noteholders that:
(a) this Agreement has been duly authorized, executed and delivered by the Company and, upon execution and delivery thereof by the parties hereto, this Agreement constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(b) the Note Purchase Agreement, as amended by this Agreement, constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(c) the execution, delivery and performance by the Company of this Agreement (i) has been duly authorized by all requisite corporate actions on the part of the Company, (ii) does not require the consent or approval of any governmental or regulatory body or agency, and (iii) will not (A) violate (1) any provision of law, statute, rule or regulation applicable to the Company or its certificate of incorporation or bylaws, (2) any order of any court or any rule, regulation or order of any other agency or government binding upon it, or (3) any provision of any material indenture, agreement or other instrument to which it is a party or by which its properties or assets are or may be bound, or (B) result in a breach or constitute (alone or with due notice or lapse of time or both) a default under any indenture, agreement or other instrument referred to in clause (iii)(A)(3) of this Section 2.1(c) ;
(d) as of the date hereof and after giving effect to this Agreement, no Default or Event of Default has occurred which is continuing; and
(e) the representations and warranties contained in Section 5 of the Note Purchase Agreement are true and correct in all material respects with the same force and effect as if made by the Company on and as of the date hereof, except to the extent that any such representation or warranty expressly relates to an earlier date.
S ECTION 3. C ONDITIONS TO E FFECTIVENESS OF A MENDMENTS AND W AIVERS .
Section 3.1. The amendments to the Note Purchase Agreement set forth herein shall not become effective until, and shall become effective when (the Effective Date ), each of the following conditions shall have been satisfied:
- 6 -
Stericycle, Inc. | Fourth Amendment |
(a) executed counterparts of this Agreement, duly executed by the Company and the holders of 51% in principal amount of the outstanding Notes, shall have been delivered to the Noteholders;
(b) the representations and warranties of the Company set forth in Section 2 hereof shall be true and correct on and with respect to the date hereof, and the execution and delivery by the Company of this Agreement shall constitute certification by the Company of the same;
(c) the Company shall have paid a fee to each holder of Notes equal to five basis points (.05%) on the outstanding principal amount of Notes held by each such holder of a Note as of the Effective Date;
(d) the Company shall have paid the fees and expenses of Chapman and Cutler LLP, special counsel to the Noteholders, incurred in connection with the negotiation, preparation, approval, execution and delivery of this Agreement for which an invoice has been provided;
(e) the Company shall have delivered copies of an amendment to each of the Bank Credit Agreement amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement; and
(f) the Company shall have delivered copies of an amendment to each of the Other Note Agreements (as defined in the Note Purchase Agreement after giving effect to this Agreement) between the Company and the purchasers named therein, each amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement.
Upon receipt and satisfaction of all of the foregoing, such amendments shall become effective.
S ECTION 4. M ISCELLANEOUS .
Section 4.1. This Agreement shall be construed in connection with and as part of the Note Purchase Agreement, and except as modified and expressly amended by this Agreement, all terms, conditions and covenants contained in the Note Purchase Agreement are hereby ratified and confirmed and shall be and remain in full force and effect.
Section 4.2 . Any and all notices, requests, certificates and other instruments, including the Notes, may refer to the Note Purchase Agreement or the Note Purchase Agreement dated as of April 30, 2015 without making specific reference to this Agreement, but nevertheless all such references shall be deemed to include this Agreement unless the context shall otherwise require.
Section 4.3. The descriptive headings of the various Sections or parts of this Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions hereof.
- 7 -
Stericycle, Inc. | Fourth Amendment |
Section 4.4. This Agreement shall be governed by and construed in accordance with New York law excluding choice-of-law principles of the law of New York that would require the application of the laws of jurisdiction other than New York.
Section 4.5. This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original, but all together only one agreement. This Agreement, together with the Note Purchase Agreement (as amended hereby) and the Notes, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.
- 8 -
I N W ITNESS W HEREOF , the parties hereto have executed this Agreement as of the Effective Date.
S TERICYCLE , I NC . | ||
By |
/s/ Daniel Ginnetti |
|
Name: Daniel Ginnetti | ||
Title: Executive Vice President and Chief | ||
Financial Officer |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
N EW Y ORK L IFE I NSURANCE C OMPANY | ||
By |
/s/ Clara Fagan |
|
Name: Clara Fagan | ||
Title: Corporate Vice President | ||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION |
||
By: | NYL Investors LLC, its Investment Manager | |
By |
/s/ Clara Fagan |
|
Name: Clara Fagan | ||
Title: Director | ||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION I NSTITUTIONALLY O WNED L IFE I NSURANCE S EPARATE A CCOUNT (BOLI 3-2) |
||
By: | NYL Investors LLC, its Investment Manager | |
By /s/ Clara Fagan | ||
Name: Clara Fagan | ||
Title: Director |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY |
||
By Northwestern Mutual Investment Management Company, LLC, its investment adviser |
||
By |
/s/ Michael H. Leske |
|
Name: Michael H. Leske | ||
Title: Managing Director | ||
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY for its Group Annuity Separate Account |
||
By |
/s/ Michael H. Leske |
|
Name: Michael H. Leske | ||
Title: Its Authorized Representative |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
S TATE F ARM L IFE I NSURANCE C OMPANY | ||
By |
/s/ Julie Hoyer |
|
Name: Julie Hoyer | ||
Title: Investment Executive | ||
By |
/s/ Rebekah L. Holt |
|
Name: Rebekah L. Holt | ||
Title: Investment Professional | ||
S TATE F ARM L IFE AND A CCIDENT A SSURANCE C OMPANY |
||
By |
/s/ Julie Hoyer |
|
Name: Julie Hoyer | ||
Title: Investment Executive | ||
By |
/s/ Rebekah L. Holt |
|
Name: Rebekah L. Holt | ||
Title: Investment Professional |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
T HRIVENT F INANCIAL FOR L UTHERANS | ||
By |
/s/ Christopher Patton |
|
Name: Christopher Patton | ||
Title: Managing Director |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
G REAT -W EST L IFE & A NNUITY I NSURANCE C OMPANY |
||
By |
/s/ Eve Hampton Darrow |
|
Name: Eve Hampton Darrow | ||
Title: Vice President, Investments | ||
By |
/s/ Ward Argust |
|
Name: Ward Argust | ||
Title: Assistant Vice President, Investments |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
T HE G UARDIAN L IFE I NSURANCE C OMPANY OF A MERICA |
||
By |
/s/ Amy Carroll |
|
Name: Amy Carroll | ||
Title: Senior Director |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
M ETROPOLITAN L IFE I NSURANCE C OMPANY | ||
G ENERAL A MERICAN L IFE I NSURANCE C OMPANY | ||
by | Metropolitan Life Insurance Company, its Investment Manager | |
By |
/s/ John A. Wills |
|
Name: John A. Wills | ||
Title: Senior Vice President and Managing | ||
Director | ||
M ET L IFE I NSURANCE K.K. | ||
by MetLife Investment Advisors, LLC, Its Investment Manager | ||
By |
/s/ C. Scott Inglis |
|
Name: C. Scott Inglis | ||
Title: Senior Vice President and Managing | ||
Director | ||
B RIGHTHOUSE L IFE I NSURANCE C OMPANY | ||
by MetLife Investment Advisors, LLC, Its Investment Manager | ||
B RIGHTHOUSE L IFE I NSURANCE C OMPANY OF NY | ||
by MetLife Investment Advisors, LLC, Its Investment Manager | ||
By |
/s/ Judith A. Gulotta |
|
Name: Judith A. Gulotta | ||
Title: Managing Director |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
N ATIONWIDE L IFE I NSURANCE C OMPANY | ||
By |
/s/ Cristian I. Donoso |
|
Name: Cristian I. Donoso | ||
Title: Authorized Signatory |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
R IVER S OURCE L IFE I NSURANCE C OMPANY | ||
By: |
/s/ Thomas W. Murphy |
|
Name: Thomas W. Murphy | ||
Title: Vice PresidentInvestments | ||
R IVER S OURCE L IFE I NSURANCE C O . OF N EW Y ORK | ||
By: |
/s/ Thomas W. Murphy |
|
Name: Thomas W. Murphy | ||
Title: Vice PresidentInvestments |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
S TATE OF W ISCONSIN I NVESTMENT B OARD | ||
By |
/s/ Christopher P. Prestigiacomo |
|
Name: Christopher P. Prestigiacomo | ||
Title: Portfolio Manager |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
C ATHOLIC F INANCIAL L IFE | ||
G UIDEONE M UTUAL I NSURANCE C OMPANY | ||
G UIDEONE P ROPERTY & C ASUALTY I NSURANCE C OMPANY |
||
By: | Advantus Capital Management, Inc. | |
By: |
/s/ Thomas B. Houghton |
|
Name: Thomas B. Houghton | ||
Title: Vice President |
Stericycle, Inc. | Fourth Amendment to | |||
2015 Note Purchase Agreement |
Exhibit 10.5
Execution Version
S TERICYCLE , I NC .
S ECOND A MENDMENT
Dated as of March 23, 2018
to
N OTE P URCHASE A GREEMENT
Dated as of October 1, 2015
Re: | 2.89% Senior Notes, Series A, due October 1, 2021 |
and
3.18% Senior Notes, Series B, due October 1, 2023
S ECOND A MENDMENT TO N OTE P URCHASE A GREEMENT
T HIS S ECOND A MENDMENT dated as of March 23, 2018 (the or this Agreement ) to the Note Purchase Agreement referred to below is between S TERICYCLE , I NC ., a Delaware corporation (the Company ), and each of the institutions which is a signatory to this Agreement (collectively, the Noteholders ).
R ECITALS :
W HEREAS , the Company and each of the Noteholders have heretofore entered into the Note Purchase Agreement dated as of October 1, 2015, as amended by that certain First Amendment thereto dated as of July 28, 2017 (as so amended, the Note Purchase Agreement ), pursuant to which the Company issued on or about October 1, 2015 (a) $150,000,000 aggregate principal amount of its 2.89% Senior Notes, Series A, due October 1, 2021 (as amended, the Series A Notes ) and (b) $150,000,000 aggregate principal amount of its 3.18% Senior Notes, Series B, due October 1, 2023 (as amended, the Series B Notes and together with the Series A Notes, collectively, the Notes );
W HEREAS , the Company and the Noteholders now desire to amend the Note Purchase Agreement and the Notes in the respects, but only in the respects, hereinafter set forth;
W HEREAS , all capitalized terms used herein and not defined herein shall have the meaning specified in the Note Purchase Agreement;
W HEREAS , all requirements of law have been fully complied with and all other acts and things necessary to make this Agreement a valid, legal and binding instrument according to its terms for the purposes herein expressed have been done or performed.
N OW , THEREFORE , upon the full and complete satisfaction of the conditions precedent to effectiveness set forth in Section 3.1 hereof, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and each of the Noteholders do hereby agree as follows:
S ECTION 1. A MENDMENTS .
Section 1.1. Section 9.9 of the Note Purchase Agreement shall be deleted in its entirety and replaced with the words Reserved..
Section 1.2. Section 9.10 of the Note Purchase Agreement shall be and is hereby amended in its entirety as follows:
Section 9.10. Note Rating. The Company will, at any time during which (a) (i) the Companys rating is A- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance
Stericycle, Inc. | Second Amendment |
Commissioners does not currently rate the Notes 1 or (b) (i) the Companys rating is BBB- or better by S&P or the equivalent rating by any other Rating Agency, (ii) the Notes do not then have a Private Letter Rating from a Rating Agency and (iii) the Securities Valuation Office of the National Association of Insurance Commissioners does not currently rate the Notes 2 or 1, at the request of the Required Holders, obtain a Private Letter Rating with respect to the Notes from one Rating Agency requested by the Required Holders.
Section 1.3. The following shall be added as new Sections 10.1(a)(iii) to the Note Purchase Agreement as follows:
(iii) If at the end of any fiscal quarter of the Company ending before or on December 31, 2019, the Unadjusted Consolidated Leverage Ratio exceeded 3.75 to 1.00, the per annum interest rate (including any Default Rate, if applicable) otherwise applicable to each series of the Notes as specified in the first paragraph thereof shall be increased as set forth below (the Primary Elevated Interest Rate ) from the date that such Unadjusted Consolidated Leverage Ratio was in excess of 3.75 to 1.00 to but not including the date that the Unadjusted Consolidated Leverage Ratio is 3.75 to 1.00 or less. The Company shall promptly, and in any event within 10 Business Days after such increase, notify the holders of the Notes in writing and specify the date of such commencement. Payment of the Primary Elevated Interest Rate shall not constitute a waiver of any Default or Event of Default hereunder. The Primary Elevated Interest Rate is determined as follows:
(A) if the Company has rating of BBB or better by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 50 basis points (0.50%);
(B) if the Company has rating of BBB- by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be an additional 75 basis points (0.75%);
(C) if the Company has no rating or a rating of BB+ or worse by S&P or the equivalent rating by any other Rating Agency, then the Primary Elevated Interest Rate shall be 125 basis points (1.25%); and
(D) in the case where the Company has two ratings from two different Rating Agencies, the lowest such rating shall control and in the case where the Company has three ratings from three different Rating Agencies, then the second lowest rating shall control (even if that rating is equal to that of the first lowest).
- 2 -
Stericycle, Inc. | Second Amendment |
provided that, for the avoidance of doubt, the MDL Leverage Increased Interest Rate and the Primary Elevated Interest Rate are not cumulative with each other and only the greater of such increase under Section 10.1(a)(ii) and (iii) shall apply at any given time; and further provided that that no such Increased Interest Rate will be used in calculating the Make-Whole Amount;
Section 1.4. Additional Definitions . Schedule B to the Note Purchase Agreement is hereby amended to insert the following definitions, each in its respective alphabetical order:
Primary Elevated Interest Rate has the meaning set forth in Section 10.1(a)(iii).
Private Letter Rating means a private letter rating from a Rating Agency which (a) is in the form and include descriptive elements required by the SVO from time to time (including (i) identifying the Notes by their Private Placement Number issued by Standard & Poors CUSIP Bureau Service and (ii) addressing the likelihood of payment of both principal and interest; provided that such requirement may be deemed satisfied if the rating is silent as to such likelihood and does not otherwise include an indication to the contrary), (b) does not include any prohibition on sharing such evidence with the SVO or any other regulatory authority having jurisdiction over the holders of Notes and (c) is delivered by the Company to the holders of Notes at least annually and promptly upon any change in such rating.
Second Amendment means the Second Amendment dated as of March 23, 2018 to this Agreement between the Company and the holders party thereto.
Unadjusted Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal
- 3 -
Stericycle, Inc. | Second Amendment |
fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements and (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Unadjusted Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Unadjusted Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Unadjusted Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Unadjusted Consolidated Leverage Ratio means, as of any date of determination, the ratio of (a)(i) Consolidated Debt as of such date minus (ii) Unrestricted Cash as of such date to (b) Unadjusted Consolidated EBITDA for the period of the four consecutive fiscal quarters most recently ended on or prior to such date.
Section 1.5. Amended Definitions. Schedule B to the Note Purchase Agreement is hereby amended by amending and restating each of the following definitions in its entirety to read as follows:
Consolidated EBITDA means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such
- 4 -
Stericycle, Inc. | Second Amendment |
period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements, (ix) as to any period, up to $10,000,000 in the aggregate of extraordinary and non-recurring cash expenses or charges in such period and (x) solely for purposes of determining compliance with Section 10.1 and Section 10.2 for any fiscal quarter ending during the period from March 31, 2018 through December 31, 2019 (and for no other purposes hereunder) up to $200,000,000 in the aggregate in any four-fiscal quarter period of cash charges associated with (A) implementation of the Companys Business Transformation and Operational Optimization Expenses (each, as described in the Companys Form 10-K for the fiscal year ended December 31, 2017), (B) internal control remediation, accounting pronouncements and related professional and consulting expenses, (C) legal and settlement related expenses and (D) up to $25,000,000 of other cash charges minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.
Increased Interest Rate means the occurrence of a MDL Leverage Increased Interest Rate or a Primary Elevated Interest Rate, as applicable.
- 5 -
Stericycle, Inc. | Second Amendment |
S ECTION 2. R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY .
Section 2.1. To induce the Noteholders to execute and deliver this Agreement, the Company represents and warrants (which representations shall survive the execution and delivery of this Agreement) to the Noteholders that:
(a) this Agreement has been duly authorized, executed and delivered by the Company and, upon execution and delivery thereof by the parties hereto, this Agreement constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(b) the Note Purchase Agreement, as amended by this Agreement, constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors rights generally;
(c) the execution, delivery and performance by the Company of this Agreement (i) has been duly authorized by all requisite corporate actions on the part of the Company, (ii) does not require the consent or approval of any governmental or regulatory body or agency, and (iii) will not (A) violate (1) any provision of law, statute, rule or regulation applicable to the Company or its certificate of incorporation or bylaws, (2) any order of any court or any rule, regulation or order of any other agency or government binding upon it, or (3) any provision of any material indenture, agreement or other instrument to which it is a party or by which its properties or assets are or may be bound, or (B) result in a breach or constitute (alone or with due notice or lapse of time or both) a default under any indenture, agreement or other instrument referred to in clause (iii)(A)(3) of this Section 2.1(c) ;
(d) as of the date hereof and after giving effect to this Agreement, no Default or Event of Default has occurred which is continuing; and
(e) the representations and warranties contained in Section 5 of the Note Purchase Agreement are true and correct in all material respects with the same force and effect as if made by the Company on and as of the date hereof, except to the extent that any such representation or warranty expressly relates to an earlier date.
S ECTION 3. C ONDITIONS TO E FFECTIVENESS OF A MENDMENTS AND W AIVERS .
Section 3.1. The amendments to the Note Purchase Agreement set forth herein shall not become effective until, and shall become effective when (the Effective Date ), each of the following conditions shall have been satisfied:
- 6 -
Stericycle, Inc. | Second Amendment |
(a) executed counterparts of this Agreement, duly executed by the Company and the holders of 51% in principal amount of the outstanding Notes, shall have been delivered to the Noteholders;
(b) the representations and warranties of the Company set forth in Section 2 hereof shall be true and correct on and with respect to the date hereof, and the execution and delivery by the Company of this Agreement shall constitute certification by the Company of the same;
(c) the Company shall have paid a fee to each holder of Notes equal to five basis points (.05%) on the outstanding principal amount of Notes held by each such holder of a Note as of the Effective Date;
(d) the Company shall have paid the fees and expenses of Chapman and Cutler LLP, special counsel to the Noteholders, incurred in connection with the negotiation, preparation, approval, execution and delivery of this Agreement for which an invoice has been provided;
(e) the Company shall have delivered copies of an amendment to each of the Bank Credit Agreement amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement; and
(f) the Company shall have delivered copies of an amendment to each of the Other Note Agreements (as defined in the Note Purchase Agreement after giving effect to this Agreement) between the Company and the purchasers named therein, each amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement.
Upon receipt and satisfaction of all of the foregoing, such amendments shall become effective.
S ECTION 4. M ISCELLANEOUS .
Section 4.1. This Agreement shall be construed in connection with and as part of the Note Purchase Agreement, and except as modified and expressly amended by this Agreement, all terms, conditions and covenants contained in the Note Purchase Agreement are hereby ratified and confirmed and shall be and remain in full force and effect.
Section 4.2 . Any and all notices, requests, certificates and other instruments, including the Notes, may refer to the Note Purchase Agreement or the Note Purchase Agreement dated as of October 1, 2015 without making specific reference to this Agreement, but nevertheless all such references shall be deemed to include this Agreement unless the context shall otherwise require.
- 7 -
Stericycle, Inc. | Second Amendment |
Section 4.3. The descriptive headings of the various Sections or parts of this Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions hereof.
Section 4.4. This Agreement shall be governed by and construed in accordance with New York law excluding choice-of-law principles of the law of New York that would require the application of the laws of jurisdiction other than New York.
Section 4.5. This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original, but all together only one agreement. This Agreement, together with the Note Purchase Agreement (as amended hereby) and the Notes, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.
- 8 -
I N W ITNESS W HEREOF , the parties hereto have executed this Agreement as of the Effective Date.
S TERICYCLE , I NC . | ||
By |
/s/ Daniel Ginnetti |
|
Name: Daniel Ginnetti | ||
Title: Executive Vice President and Chief | ||
Financial Officer |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
M ETROPOLITAN L IFE I NSURANCE C OMPANY | ||
G ENERAL A MERICAN L IFE I NSURANCE C OMPANY | ||
by | Metropolitan Life Insurance Company, its Investment Manager | |
By |
/s/ John A. Wills |
|
Name: John A. Wills | ||
Title: Senior Vice President and Managing | ||
Director | ||
B RIGHTHOUSE L IFE I NSURANCE C OMPANY | ||
by MetLife Investment Advisors, LLC, Its Investment Manager | ||
By |
/s/ Judith A. Gulotta |
|
Name: Judith A. Gulotta | ||
Title: Managing Director | ||
E RIE F AMILY L IFE I NSURANCE C OMPANY | ||
by MetLife Investment Advisors, LLC, Its Investment Manager | ||
By |
/s/ Judith A. Gulotta |
|
Name: Judith A. Gulotta | ||
Title: Managing Director |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY |
||
By | Northwestern Mutual Investment Management Company, LLC, its investment adviser | |
By |
/s/ Michael H. Leske |
|
Name: Michael H. Leske | ||
Title: Managing Director | ||
T HE N ORTHWESTERN M UTUAL L IFE I NSURANCE C OMPANY for its Group Annuity Separate Account |
||
By |
/s/ Michael H. Leske |
|
Name: Michael H. Leske | ||
Title: Its Authorized Representative |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
N EW Y ORK L IFE I NSURANCE C OMPANY | ||||
By |
/s/ Clara Fagan |
|||
Name: Clara Fagan | ||||
Title: Corporate Vice President | ||||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION |
||||
By: | NYL Investors LLC, its Investment Manager | |||
By |
/s/ Clara Fagan |
|||
Name: Clara Fagan | ||||
Title: Director | ||||
N EW Y ORK L IFE I NSURANCE AND A NNUITY C ORPORATION I NSTITUTIONALLY O WNED L IFE I NSURANCE S EPARATE A CCOUNT (BOLI 3) |
||||
By: | NYL Investors LLC, its Investment Manager | |||
By |
/s/ Clara Fagan |
|||
Name: Clara Fagan | ||||
Title: Director |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
The Bank of New York Mellon, a banking | ||||
CORPORATION ORGANIZED UNDER THE LAWS OF N EW Y ORK , NOT IN ITS INDIVIDUAL CAPACITY BUT SOLELY AS T RUSTEE UNDER THAT CERTAIN T RUST A GREEMENT DATED AS OF J ULY 1 ST , 2015 BETWEEN N EW Y ORK L IFE I NSURANCE C OMPANY , AS G RANTOR , J OHN H ANCOCK L IFE I NSURANCE C OMPANY (U.S.A.), AS B ENEFICIARY , J OHN H ANCOCK L IFE I NSURANCE C OMPANY OF N EW Y ORK , AS B ENEFICIARY , AND T HE B ANK OF N EW Y ORK M ELLON , AS T RUSTEE | ||||
By: | New York Life Insurance Company, its attorney-in-fact | |||
By |
/s/ Clara Fagan |
|||
Name: Clara Fagan | ||||
Title: Corporate Vice President |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
S TATE F ARM L IFE I NSURANCE C OMPANY | ||
By |
/s/ Julie Hoyer |
|
Name: Julie Hoyer | ||
Title: Investment Executive | ||
By |
/s/ Rebekah L. Holt |
|
Name: Rebekah L. Holt | ||
Title: Investment Professional | ||
S TATE F ARM L IFE AND A CCIDENT A SSURANCE C OMPANY |
||
By |
/s/ Julie Hoyer |
|
Name: Julie Hoyer | ||
Title: Investment Executive | ||
By |
/s/ Rebekah L. Holt |
|
Name: Rebekah L. Holt | ||
Title: Investment Professional |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
N ATIONWIDE L IFE I NSURANCE C OMPANY | ||
By |
/s/ Cristian I. Donoso |
|
Name: Cristian I. Donoso | ||
Title: Authorized Signatory |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
T HRIVENT F INANCIAL FOR L UTHERANS | ||
By |
/s/ Christopher H. Patton |
|
Name: Christopher Patton | ||
Title: Managing Director |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
S TATE OF W ISCONSIN I NVESTMENT B OARD | ||
By |
/s/ Christopher P. Prestigiacomo |
|
Name: Christopher P. Prestigiacomo | ||
Title: Portfolio Manager |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
A UTO -O WNERS I NSURANCE C OMPANY | ||
By: | Fort Washington Investment Advisors, | |
as investment adviser | ||
By |
/s/ Douglas E. Kelsey |
|
Name: Douglas E. Kelsey | ||
Title: VP-Private Placements | ||
By |
/s/ Roger M. Lanham |
|
Name: Roger M. Lanham | ||
Title: Co-Chief Investment Officer | ||
A UTO -O WNERS L IFE I NSURANCE C OMPANY | ||
By: | Fort Washington Investment Advisors, | |
as investment adviser | ||
By |
/s/ Douglas E. Kelsey |
|
Name: Douglas E. Kelsey | ||
Title: VP-Private Placements | ||
By |
/s/ Roger M. Lanham |
|
Name: Roger M. Lanham | ||
Title: Co-Chief Investment Officer |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
A MERICAN U NITED L IFE I NSURANCE C OMPANY | ||
By: |
/s/ Michael I. Bullock |
|
Name: Michael I. Bullock | ||
Title: VP, Private Placements | ||
T HE S TATE L IFE I NSURANCE C OMPANY | ||
By: | American United Life Insurance Company | |
Its: Agent | ||
By: |
/s/ Michael I. Bullock |
|
Name: Michael I. Bullock | ||
Title: VP, Private Placements |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
A MERITAS L IFE I NSURANCE C ORP . SUCCESSOR BY MERGER TO A CACIA L IFE I NSURANCE C OMPANY |
||
A MERITAS L IFE I NSURANCE C ORP . OF N EW Y ORK | ||
By: Ameritas Investment Partners Inc., as Agent | ||
By: |
/s/ Tina Udell |
|
Name: Tina Udell | ||
Title: Vice President & Managing Director |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
PHL V ARIABLE I NSURANCE C OMPANY | ||
By: Nassau Asset Management LLC, as Investment Manager | ||
By |
/s/ Christopher Wilkos |
|
Name: Christopher Wilkos | ||
Title: Chief Investment Officer |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
W OODMEN OF T HE W ORLD L IFE I NSURANCE S OCIETY |
||
By: |
/s/ Shawn Bengtson |
|
Name: Shawn Bengtson | ||
Title: Vice President, Investment |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |
Accepted and Agreed to:
S OUTHERN F ARM B UREAU L IFE I NSURANCE C OMPANY |
||
By |
/s/ David Divine |
|
Name: David Divine | ||
Title: Senior Portfolio Manager |
Stericycle, Inc. | Second Amendment to | |||
2015 Note Purchase Agreement |